Skip to main content

Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Accept all cookies Reject all non-essential cookies Find out more

Tan Group: Next-Generation Vaccines against Infectious Diseases

  • MRC Translational Immune Discovery Unit
  • Nuffield Division of Clinical Laboratory Sciences
Covid-19 virus © Image by Freepik

Our group focuses on developing next-generation protein nanoparticle-based vaccines and antibody therapeutics against infectious diseases, with a particular focus on betacoronaviruses. We are especially interested in understanding how the architecture of protein nanoparticle vaccines influences their immunogenicity, and in investigating mucosal vaccine immunity to improve vaccine design. 

Our team

Selected publications

Collaborators

  • Professor Pamela Bjorkman (Caltech, USA)
  • Professor Mark Howarth (University of Cambridge)
  • Professor William James (Sir William Dunn School of Pathology)
  • Professor Omer Dushek (Sir William Dunn School of Pathology)
  • Professor Phillip Kukura (Kavli Institute for Nanoscience Discovery)
  • Dr Peter Wing (Chinese Academy of Medical Sciences Oxford Institute)
  • Dr Pablo Cespedes Donoso (Chinese Academy of Medical Sciences Oxford Institute)
  • Professor Neelika Malavige (University of Sri Jayewardenepura)
  • Professor Kuan-Ying Arthur Huang (National Taiwan University)

Related research themes

We seek to bridge the ‘innovation gap’ between ‘basic’ research in the laboratory and tangible benefits for patients. Our researchers aim to develop novel approaches to treating disease and we have particular strengths in evaluating technologies such as antibody therapy and gene therapy, and using new techniques for target discovery. Many of our researchers collaborate with biotech and industry partners to accelerate progress along the drug discovery pipeline and assess these new treatments in the clinic.
Emerging Therapies and Drug Discovery
A raft of cellular and molecular biology techniques underpin much of the work we do to elucidate the mechanisms of disease. We use established techniques to answer new questions and also develop our own novel and unique methodologies to drive further innovation.
Cellular and Molecular Biology
We are committed to translating our innovative research into clinical benefit. From new methods of diagnosing chronic conditions, to finding the latest treatments for diabetes, cancer, heart disease, stroke and rare diseases, our department is involved in hundreds of clinical studies every year.
Clinical Studies and Trials